Mark A. Dickson, MD

About Me

I am a medical oncologist who specializes in the treatment of sarcomas of soft tissue and bone, Kaposi’s sarcoma, and melanoma. My research is focused on the development of new drugs, including targeted small molecules and antibodies, to treat these diseases.  In particular, I study new drugs that block pathways and proteins critical for cancer growth such as the cell cycle pathway in liposarcoma, the Aurora kinase proteins in soft tissue sarcoma, and the Notch pathway in melanoma.  My research includes work in HIV-associated Kaposi’s sarcoma in concert with the AIDS Malignancy consortium.  My goal is to find newer, more-effective, and less-toxic therapies to improve the lives of people living with cancer.

  • Clinical Expertise: Sarcomas of Soft Tissue and Bone; Kaposi’s Sarcoma; Melanoma
  • Languages Spoken: English
  • Education: MD, Columbia University
  • Residencies: Internal Medicine - New York Presbyterian/Weill Cornell Medical Center
  • Fellowships: Hematology/Oncology - Memorial Sloank Kettering Cancer Center
  • Board Certifications: Internal Medicine; Hematology; Medical Oncology


Visit PubMed for a full listing of Mark A. Dickson’s journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.


Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.

Learn more Arrow rightAn icon showing an arrow pointing to the right.